Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano (Nasdaq: BNGO) announced a multicenter study published April 2026 showing optical genome mapping (OGM) can outperform traditional cytogenetic methods in multiple myeloma (MM). The study analyzed 211 MM samples, found high concordance with karyotyping, FISH and NGS, and reported OGM identified additional pathogenic findings in ~30% of subjects.
OGM identified relevant abnormalities in 92% of cases previously called normal by karyotype and resolved 82% of samples that previously failed karyotype, and detected complex events (chromoanagenesis) in ~29% of samples.
Bionano Genomics (Nasdaq: BNGO) reported Q4 2025 revenue of $8.0M (down 3% YoY) and full‑year 2025 revenue of $28.5M (down 7% YoY). Gross margin improved to 46% FY and installed OGM base reached 387 systems. Company guided 2026 revenue to $30–33M and Q1 2026 to $6.5–6.7M.
Operating expenses were cut significantly, cash and equivalents were $29.6M, and CMS increased the 2026 CLFS payment determination by 47% for OGM hematologic code.
Bionano (NASDAQ: BNGO) reported that 12 optical genome mapping (OGM) studies were presented at the 2026 ACMG Annual Meeting (March 14–18), a two-fold increase versus 2025. Presentations included four oral talks and eight posters across cancer genomics and constitutional genetic disorders.
The presentations highlighted OGM's ability to detect structural variants missed by other methods; a Greenwood Genetic Center workshop and a Baylor Genetics commercial OGM service release were also noted.
Bionano Genomics (Nasdaq: BNGO) will report fourth quarter and full year 2025 financial results and host a conference call and live webcast on Monday, March 23, 2026 at 4:30 p.m. ET.
Participants can access the live webcast via the company’s Investors page; a replay will be archived on the investor relations site for at least 30 days. Contact details and registration links are provided for investors and media.
Bionano Genomics (Nasdaq: BNGO) summarized Day 4 highlights from Symposium 2026 on Feb 27, 2026, with >1,250 registrants, 35 external speakers, 33 presentations and 50 posters.
Speakers described scaling optical genome mapping (OGM) with automation, VIA software, Ionic nucleic acid isolation, and Stratys throughput claims, citing sample-volume targets, cost comparisons with long-read sequencing, and new digital karyotyping tools.
Bionano (Nasdaq: BNGO) highlighted Day 3 of Symposium 2026 on Feb 26, 2026, focused on optical genome mapping (OGM) in constitutional genetic disorders. Attendance exceeded 1,200 participants from >73 countries and the online poster hall featured 50 posters. Presentations reported study detection rates, case examples, and VIA software use for SV interpretation.
Bionano Genomics (Nasdaq: BNGO) reported Day 2 highlights from Symposium 2026 focused on oncology and bioprocessing applications of Optical Genome Mapping (OGM). Presentations showed OGM detecting complex structural variants in multiple myeloma, rare sarcomas, and engineered cell lines, and discussed FDA and ISSCR recognition for genome-integrity analysis.
Attendance exceeded 1,150 registrants from 73 countries; session recordings will be available on Bionano's YouTube channel.
Bionano Genomics (Nasdaq: BNGO) reported Day 1 highlights from Symposium 2026 focused on optical genome mapping (OGM) for hematologic malignancies. Nine presentations showed OGM's high concordance with traditional cytogenetics and its ability to resolve complex structural variants, integrate with NGS via VIA, and rescue failed assays.
More than 1,000 attendees from 70 countries participated; session recordings will be available on the company YouTube channel, with the live panel Q&A excluded from on-demand.
Bionano (Nasdaq: BNGO) announced Bionano Symposium 2026, a free virtual event Feb 23-26, 2026 showcasing optical genome mapping (OGM) research and applications.
The four-day program features >30 international researchers, sessions on oncology, hematologic malignancies, constitutional genetics, bioprocessing, and demonstrations of Ionic, Saphyr, Stratys, and VIA.
Bionano Genomics (Nasdaq: BNGO) highlighted a peer-reviewed study showing optical genome mapping (OGM) can detect genomic alterations introduced by gene editing methods in human iPSC lines. The study reports OGM sensitivity to variant allele fractions as low as 5%, found variable transgene insertion counts by technology, and identified complex structural variants missed by traditional methods.
Findings suggest OGM may serve as a complementary QC tool to assess genome integrity and reveal potentially pathogenic off-target rearrangements in engineered cell lines used for therapeutic development.